Gavin Wood - 02 Sep 2025 Form 4 Insider Report for Adaptimmune Therapeutics PLC (ADAP)

Reporting relationship: Chief Financial Officer
Issuer ticker: ADAP
Reported as of: 02 Sep 2025
Net transaction value: -$950
SEC form: 4
Accepted by SEC: 03 Sep 2025, 17:00:21 UTC
Prior SEC filing: 17 Jan 2024
Source filing: View source filing
Reporting owner signature: /s/ Gavin Wood

Key filing fact

Gavin Wood filed Form 4 for Adaptimmune Therapeutics PLC (ADAP) on 03 Sep 2025.

Key facts

This page summarizes Gavin Wood's Form 4 filing for Adaptimmune Therapeutics PLC (ADAP).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 03 Sep 2025, 17:00.

Change

Previous filing in this sequence was filed on 17 Jan 2024.
Current net transaction value: -$950.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001577539 Primary reporting owner

Wood Gavin

Relationship: Chief Financial Officer
Address: C/O ADAPTIMMUNE THERAPEUTICS PLC,, 60 JUBILEE AVENUE, MILTON PARK, ABINGDON, UNITED KINGDOM
Signature: /s/ Gavin Wood
Signature date: 03 Sep 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ADAP transaction

Ordinary Shares with a nominal value of GBP0.001 per share

Sale

Transaction value: $950
Shares: -96,000
Change %: -100%
Price: $0.009900^*
Shares after: 0
Date: 02 Sep 2025
Ownership: Direct
Footnotes: F1, F2, F3, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

The ordinary shares whose sale is reported on this line are represented by American Depositary Shares ("ADS") and are held in the form of ADSs by the Reporting Person. Each ADS represents six ordinary shares of the Issuer.

Footnote F2

The 96,000 ordinary shares reported in Column 4 are represented by 16,000 ADSs.

Footnote F3

The price reported in Column 4 of $0.0099 per ordinary share is derived from the sale price of $0.0594 per ADS divided by six. These ADSs were sold in multiple transactions at a price of $0.0594. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote.

Footnote F4

The Reporting Person does not hold any ordinary shares in the form of ADSs following this transaction. However, the Reporting Person holds nominal cost options and other options covering an aggregate of 11,140,760 ordinary shares of the Issuer.